Page 55 - Read Online

Aydin et al. J Transl Genet Genom. 2025;9:406-26 https://dx.doi.org/10.20517/jtgg.2025.108 Page 422

the corresponding author upon reasonable request.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Chiu W, Hsun YH, Chang KJ, et al. Current genetic survey and potential gene-targeting therapeutics for neuromuscular diseases. Int J
Mol Sci. 2020;21:9589. DOI PubMed PMC
2. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13. DOI
PubMed PMC
3. Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: current treatment and emerging exon
skipping and gene therapy approach. Eur J Pharmacol. 2023;947:175675. DOI PubMed
4. Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22:917-
34. DOI PubMed
5. Suzuki H, Aoki Y, Kameyama T, et al. Endogenous multiple exon skipping and back-splicing at the DMD mutation hotspot. Int J
Mol Sci. 2016;17:1722. DOI PubMed PMC
6. Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270:3733-49.
DOI
7. Bez Batti Angulski A, Hosny N, Cohen H, et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front
Physiol. 2023;14:1183101. DOI PubMed PMC
8. Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an
evidence review. Orphanet J Rare Dis. 2017;12:79. DOI PubMed PMC
9. Qian C, Klimchak AC, Szabo SM, Popoff E, Iannaccone ST, Gooch KL. Observing the clinical course of Duchenne muscular
dystrophy in medicaid real-world healthcare data. Adv Ther. 2024;41:2519-30. DOI PubMed PMC
10. Grounds MD, Terrill JR, Al-Mshhdani BA, Duong MN, Radley-Crabb HG, Arthur PG. Biomarkers for Duchenne muscular
dystrophy: myonecrosis, inflammation and oxidative stress. Dis Model Mech. 2020;13:dmm043638. DOI PubMed PMC
11. Szigyarto C. Duchenne muscular dystrophy: recent advances in protein biomarkers and the clinical application. Expert Rev
Proteomics. 2020;17:365-75. DOI PubMed
12. Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15:840-8. DOI PubMed
PMC
13. Reinig AM, Mirzaei S, Berlau DJ. Advances in the treatment of Duchenne muscular dystrophy: new and emerging
pharmacotherapies. Pharmacotherapy. 2017;37:492-9. DOI PubMed
14. Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533-
45. DOI PubMed PMC
15. Dadgar S, Wang Z, Johnston H, et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J
Cell Biol. 2014;207:139-58. DOI PubMed PMC
16. Choi IY, Lim H, Estrellas K, et al. Concordant but varied phenotypes among Duchenne muscular dystrophy patient-specific
myoblasts derived using a human iPSC-based model. Cell Rep. 2016;15:2301-12. DOI
17. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat
Commun. 2019;10:1523. DOI PubMed PMC
18. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization
and interpretation. PLoS One. 2010;5:e13984. DOI PubMed PMC
19. Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and
chemical interactions. Protein Sci. 2021;30:187-200. DOI
20. Huang HY, Lin YC, Cui S, et al. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target
interactions. Nucleic Acids Res. 2022;50:D222-30. DOI
21. Han H, Shim H, Shin D, et al. TRRUST: a reference database of human transcriptional regulatory interactions. Sci Rep.